0.2%酒石酸溴莫尼定联合0.25%倍他洛尔的短期降眼压疗效及安全性研究

Effects and safety of brimonidine 0.2% and betaxolol 0.25% combined therapy for glaucoma

目的观察0．2％酒石酸溴莫尼定滴眼液联合应用0．25％倍他洛尔混悬液对原发性开角型青光眼及高眼压症患者3个月的降眼压疗效及安全性。设计前瞻性病例系列。研究对象原发性开角型青光眼32例（57眼），高眼压症14例（27眼）。方法给予0．2％酒石酸溴莫尼定滴眼液及0．25％倍他洛尔混悬液早晚各2次点眼，分别于用药后2、4、8、12周复查，观察用药前后的眼压及不良反应，共观察3个月。主要指标眼压、不良反应。结果用药后2～12周眼压平均降低5，7l～7．38mmHg，平均降幅为21．94％～39．01％；左右眼间降眼压效果无明显区别（P〉0．05）；男女性别之间降眼压效果亦无显著差异（P〉0．05）。随访期间，3例患者出现不能耐受的眼部刺激症状而退出试验。7例（8．33％）出现眼分泌物增多；5例（5．95％）出现眼部刺痛；10例（11．9％）出现眼部烧灼感；7例出现口苦（8．33％）；3例（3．57％）出现眉弓胀痛伴头痛；视力及前节无显著变化。结论本文的短期研究显示，0．2％酒石酸溴莫尼定滴眼液联合0．25％倍他洛尔混悬液对原发性开角型青光眼及高眼压症患者具有较好的降眼压效果，副作用少。

Objective To evaluate the short-time effects and safety of brimonidine 0.2% and betaxolol 0.25% combined therapy in the treatment of patients with primary open-angle glaucoma （POAG） and ocular hypertension patients. Design Prospective case series. Participants POAG 32 cases （57 eyes）, 14 cases （27 eyes） of ocular hypertension. Methods after a washing out phase, Bri- monidine 0.2% combined Betaxolol 0.25% were administered to the participants twice daily. The Goldman intraocular pressure （lOP）and the side effects were observed before and after 2, 4, 8, 12 weeks the administration of the eye drops. The observing duration was 3 months. Main Outcome Measures IOP, adverse reaction. Results After two to twelve weeks of the combined madication, the average IOP decreased 5.71～7.38 mmHg, with an average decline of 21.94%～39.01% There was no significant difference between right and left eye （P〉0.05）, and between the genders （P〉0.05）. During follow-up, 3 patients exited the test because can＇t tolerate eye irritation. 7 cases （8.33%） in eye secretions increase; 5 cases （5.95%） experienced eye hurt; the burning sensation in the eye in 10 cases （11.9%）; 7 cases with bitter tast （8.33%）; three cases （3.57%） appeared eyebrow with headache pain; the vision and anterior segment had no sig- nificant changes. Conclusion The short-time research results show that brimonidine 0.2% and betaxolol 0.25% combined therapy has beneficial IOP-lowering effects and few side effects for the patients with POAG or ocular hypertension.